Tzu Chi Medical Journal

REVIEW ARTICLE
Year
: 2021  |  Volume : 33  |  Issue : 1  |  Page : 22--28

Updates on the diagnosis and management of multicentric Castleman disease


Ya-Ju Wu1, Kuei-Ying Su2 
1 Division of Critical Care Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
2 Division of Rheumatology and Immunology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan; School of Medicine, Tzu Chi University, Hualien, Taiwan

Correspondence Address:
Dr. Kuei-Ying Su
Division of Rheumatology and Immunology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Section 3, Chung-Yang Road, Hualien
Taiwan

Multicentric Castleman disease (MCD) is an uncommon systemic lymphoproliferative disease. The diagnosis of this disease is typically challenging and requires collaboration between clinicians and pathologists. Moreover, it is important to exclude other diseases (such as malignancies, autoimmune diseases, and infectious diseases) that have similar clinical manifestations and pathological findings. Patients with untreated severe MCD have high mortality due to devastating cytokine storms. Thus, early diagnosis and prompt treatment is a key imperative. The diagnosis of MCD is based on the clinical signs of systemic inflammation, serological tests, and typical pathological features. In this review article, we provide an overview of MCD with a focus on the emerging evidence pertaining to its diagnosis and treatment.


How to cite this article:
Wu YJ, Su KY. Updates on the diagnosis and management of multicentric Castleman disease.Tzu Chi Med J 2021;33:22-28


How to cite this URL:
Wu YJ, Su KY. Updates on the diagnosis and management of multicentric Castleman disease. Tzu Chi Med J [serial online] 2021 [cited 2021 Jan 23 ];33:22-28
Available from: https://www.tcmjmed.com/article.asp?issn=1016-3190;year=2021;volume=33;issue=1;spage=22;epage=28;aulast=Wu;type=0